Alemtuzumab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Post-marketing information
Dear Healthcare Professional Letters
Subsidy Information and Financing Scheme
No
Active ingredient: Alemtuzumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
01/07/2026 Disease-modifying therapies for treating multiple sclerosis (opens in new tab)
The Ministry of Health’s Drug Advisory Committee has recommended:
Cladribine 10 mg tablet for treating relapsing-remitting multiple sclerosis,
Fingolimod 0.25 mg and 0.5 mg capsules for treating relapsing-remitting multiple sclerosis, and
Siponimod 0.25 mg and 2 mg tablets for treating adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity.
Funding status
[R] Cladribine 10 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2026.
[R] Fingolimod (Gilenya) 0.25 mg and 0.5 mg capsules are recommended for reclassification from the MAF to the Standard Drug List (SDL) from 1 September 2026.
[R] Siponimod 0.25 mg and 2 mg tablets are recommended for inclusion on the MAF for the abovementioned indication from 4 January 2022.
[NR] SDL subsidy and MAF assistance do not apply to any formulations or strengths of alemtuzumab, dimethyl fumarate, interferon beta-1a, natalizumab, ocrelizumab, ofatumumab or teriflunomide for treating adults or children with any form of multiple sclerosis.